HowShorted

How shorted is BioXcel Therapeutics, Inc.?

More shorted than 91% of the 2,877 ranked US companies

15.57%
of shares outstanding reported short · settlement date 31 Jul 2026
vs previous report
+0.63
5 reports (~10 weeks)
+2.44
Aggregate net short position time series for BioXcel Therapeutics, Inc.
Embed this chart

Paste this snippet to embed the interactive chart. It updates with each FINRA report and keeps the source attribution. Preview

Cite this page

History

Settlement dateShort %Change
31 Jul 202615.57%+0.63
15 Jul 202614.94%+1.41
30 Jun 202613.53%−2.41
15 Jun 202615.94%+2.92
29 May 202613.02%−0.11
15 May 202613.13%−2.54
30 Apr 202615.67%+1.09
15 Apr 202614.58%+2.35
31 Mar 202612.23%−0.60
13 Mar 202612.83%+4.25
27 Feb 20268.58%−0.28
13 Feb 20268.86%+1.88
30 Jan 20266.98%+0.73
15 Jan 20266.25%+1.54
31 Dec 20254.71%+0.23
15 Dec 20254.48%+0.32
28 Nov 20254.16%−3.07
14 Nov 20257.23%−2.40
31 Oct 20259.63%+1.79
15 Oct 20257.84%−3.08
30 Sep 202510.92%+1.00
15 Sep 20259.92%−0.50
15 Aug 202510.42%+5.58
31 Jul 20254.84%–

Frequently asked questions

How shorted is BioXcel Therapeutics, Inc. right now?
15.57% of BioXcel Therapeutics, Inc.'s (BTAI) shares outstanding were reported short for settlement date 31 Jul 2026, per FINRA's consolidated short interest report.
What does this number include?
FINRA member firms must report their short positions in all US equities twice a month; FINRA consolidates them per security. We divide that official share count by the company's shares outstanding from its SEC filings. This is the regulatory figure, not a daily estimate.
Why does it only update twice a month?
US short interest is reported for settlement on the 15th and the last business day of each month, and FINRA publishes the consolidated figures about nine business days later. That cadence is set by regulation; no daily official figure exists.
Which funds are short?
US public short interest is aggregate-only: individual short sellers are not named. Only some EU markets publish named positions.